Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.37M$1.37Mderived−39.4% vs Q4 2015 Net Income-$1.40M-$1.40MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,765,152N/M Operating Cash Flowderived-$161,702N/M Free Cash Flowderived-$282,887N/M Margins · derivedOperating margin-129.1%−43.7 pt vs Q4 2015
Net margin-102.3%−16.6 pt vs Q4 2015
ended Mar 31, 2016 · filed Jul 14, 2016 · 105 d after period end